(ILMN) Illumina - NASDAQ
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 25.250m USD | Total Return: 82% in 12m
Avg Turnover: 283M
EPS Trend: 95.4%
Qual. Beats: 0
Rev. Trend: -79.1%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Rs Leader, Idiosyncratic Leader
Illumina, Inc. (ILMN) is a global provider of sequencing and array-based solutions for genetic and genomic analysis. The company develops and manufactures instruments, reagents, and flow cells used for whole-genome sequencing, targeted resequencing, and noninvasive prenatal testing. Its client base spans academic institutions, government laboratories, hospitals, and biotechnology firms.
The company operates within the Life Sciences Tools & Services sector, characterized by high barriers to entry due to complex intellectual property and substantial research and development requirements. Illumina utilizes a razor-and-blade business model, where the installation of proprietary sequencing hardware generates a recurring revenue stream through the continuous sale of specialized consumables.
Strategic collaborations, such as its partnership with Labcorp Holdings Inc., focus on applying sequencing technology to oncology treatments and pediatric disease research. For a more comprehensive look at these financial drivers, consider reviewing the detailed metrics on ValueRay. Illumina is headquartered in San Diego and maintains a direct distribution network across major global markets including Greater China and Europe.
- Consumables revenue growth from high-throughput sequencing drives recurring cash flow
- Next-generation NovaSeq X instrument adoption determines long-term hardware market share
- Clinical diagnostic expansion in oncology and prenatal testing accelerates revenue diversification
- GRAIL divestiture execution and regulatory compliance impact operational margin stability
- R&D spending and competitive pricing pressure from emerging sequencing rivals affect profitability
| Net Income: 853.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.02 > 1.0 |
| NWC/Revenue: 26.69% < 20% (prev 28.43%; Δ -1.74% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.13b > Net Income 853.0m |
| Net Debt (1.94b) to EBITDA (1.41b): 1.38 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (154.0m) vs 12m ago -3.14% < -2% |
| Gross Margin: 67.66% > 18% (prev 66.38%; Δ 1.28% > 0.5%) |
| Asset Turnover: 68.93% > 50% (prev 70.16%; Δ -1.23% > 0%) |
| Interest Coverage Ratio: 11.37 > 6 (EBIT TTM 1.14b / Interest Expense TTM 100.0m) |
| A: 0.18 (Total Current Assets 2.74b - Total Current Liabilities 1.57b) / Total Assets 6.56b |
| B: -0.04 (Retained Earnings -258.0m / Total Assets 6.56b) |
| C: 0.18 (EBIT TTM 1.14b / Avg Total Assets 6.37b) |
| D: 0.69 (Book Value of Equity 2.68b / Total Liabilities 3.88b) |
| Altman-Z'' = 2.97 = A |
| DSRI: 1.02 (Receivables 738.0m/714.0m, Revenue 4.39b/4.34b) |
| GMI: 0.98 (GM 66.38% / 67.66%) |
| AQI: 1.10 (AQ_t 0.41 / AQ_t-1 0.37) |
| SGI: 1.01 (Revenue 4.39b / 4.34b) |
| TATA: -0.04 (NI 853.0m - CFO 1.13b) / TA 6.56b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of June 17, 2026, the stock is trading at USD 164.28 with a total of 1,242,168 shares traded.
Over the past week, the price has changed by +2.66%,
over one month by +16.09%,
over three months by +37.73% and
over the past year by +82.03%.
Illumina has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold ILMN.
- StrongBuy: 8
- Buy: 3
- Hold: 6
- Sell: 2
- StrongSell: 1
| Analysts Target Price | 147.2 | -10.4% |
P/E Trailing = 30.2886
P/E Forward = 30.7692
P/S = 5.7479
P/B = 9.1012
P/EG = 2.8237
Revenue TTM = 4.39b USD
EBIT TTM = 1.14b USD
EBITDA TTM = 1.41b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 579.0m USD (from shortTermDebt, last quarter)
Debt = 3.10b USD (from shortLongTermDebtTotal, last quarter) + Leases 555.0m
Net Debt = 1.94b USD (calculated: Debt 3.10b - CCE 1.16b)
Enterprise Value = 27.2b USD (25.3b + Debt 3.10b - CCE 1.16b)
Interest Coverage Ratio = 11.37 (Ebit TTM 1.14b / Interest Expense TTM 100.0m)
EV/FCF = 27.50x (Enterprise Value 27.2b / FCF TTM 989.0m)
FCF Yield = 3.64% (FCF TTM 989.0m / Enterprise Value 27.2b)
FCF Margin = 22.52% (FCF TTM 989.0m / Revenue TTM 4.39b)
Net Margin = 19.43% (Net Income TTM 853.0m / Revenue TTM 4.39b)
Gross Margin = 67.66% ((Revenue TTM 4.39b - Cost of Revenue TTM 1.42b) / Revenue TTM)
Gross Margin QoQ = 68.19% (prev 67.07%)
Tobins Q-Ratio = 4.15 (Enterprise Value 27.2b / Total Assets 6.56b)
Interest Expense / Debt = 3.23% (Interest Expense 100.0m / Debt 3.10b)
Taxrate = 19.60% (208.0m / 1.06b)
NOPAT = 914.1m (EBIT 1.14b * (1 - 19.60%))
Current Ratio = 1.75 (Total Current Assets 2.74b / Total Current Liabilities 1.57b)
Debt / Equity = 1.16 (Debt 3.10b / totalStockholderEquity, last quarter 2.68b)
Debt / EBITDA = 1.38 (Net Debt 1.94b / EBITDA 1.41b)
Debt / FCF = 1.97 (Net Debt 1.94b / FCF TTM 989.0m)
Total Stockholder Equity = 2.51b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.39% (Net Income 853.0m / Total Assets 6.56b)
RoE = 33.99% (Net Income TTM 853.0m / Total Stockholder Equity 2.51b)
RoCE = 28.43% (EBIT 1.14b / Capital Employed (Equity 2.51b + L.T.Debt 1.49b))
RoIC = 17.08% (NOPAT 914.1m / Invested Capital 5.35b)
WACC = 9.09% (E(25.3b)/V(28.3b) * Re(9.89%) + D(3.10b)/V(28.3b) * Rd(3.23%) * (1-Tc(0.20)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -57.95 | Cagr: -1.41%
[DCF] Terminal Value 75.40% ; FCFF base≈941.0m ; Y1≈1.07b ; Y5≈1.53b
[DCF] Fair Price = 122.2 (EV 20.4b - Net Debt 1.94b = Equity 18.5b / Shares 151.3m; r=9.09% [WACC]; 5y FCF grow 13.81% → 2.50% )
EPS Correlation: 95.43 | EPS CAGR: 124.7% | SUE: 0.36 | # QB: 0
Revenue Correlation: -79.09 | Revenue CAGR: -1.51% | SUE: 1.09 | # QB: 3
EPS current Quarter (2026-06-30): EPS=1.23 | Chg30d=+0.24% | Revisions=-53% | Analysts=16
EPS next Quarter (2026-09-30): EPS=1.37 | Chg30d=+0.20% | Revisions=+18% | Analysts=16
EPS current Year (2026-12-31): EPS=5.23 | Chg30d=+0.08% | Revisions=+81% | GrowthEPS=+8.0% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=5.92 | Chg30d=+0.22% | Revisions=+62% | GrowthEPS=+13.4% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: +81%